Login / Signup

Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy.

Daniel Louis Hertz
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
testing would increase clinical adoption and ensure that all patients receive maximally safe and effective FP treatment.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • squamous cell carcinoma
  • radiation therapy
  • patient reported outcomes